New Product: Recombinant Human CRP Antigen

Published: 10.05.2022
28 Apr, 2022
Dr. Jorge Díaz-Garzón, Winner of the Third EFLM-HyTest Cardiac Marker Award

We warmly congratulate Dr. Jorge Díaz-Garzón, winner of the third EFLM-HyTest Cardiac Marker award, who finally received his award at the IFCC-EFLM European Congress - EuroMedLab!

Read more
31 Mar, 2022
New! Monoclonal Anti-neurofilament Light Antibodies

Neurofilaments are the main cytoskeletal structure proteins in neurons. They are about 10 nm in diameter, thicker than actin and thinner than myosin, and are thus classed as intermediate filaments (IFs). Neurofilaments comprise four different subunits, the stoichiometry of which varies depending on the maturity of the neuron.

Read more
30 Mar, 2022
SensUs Sponsorship

HyTest sponsored SensUs in 2017 when the target molecule was NT-proBNP. In 2022 the aim is to make biosensors for measuring acute inflammation focusing on sepsis. Target molecule is interleukin-6 and we will again sponsor SensUs teams by providing IL-6 antibodies and antigens to them.

Read more
02 Mar, 2022
HyTest Operations During the Conflict in Europe

The escalation of the conflict between Russia and Ukraine last week has led to a crisis in Europe.
We are following the situation closely and give all our sympathies to the victims and the people affected by the war.

Read more
01 Mar, 2022
Troponin Products for Hs-cTnI Assay Development

Acute myocardial infarction (AMI) causes damage of heart muscle and the release of troponin complexes in patients’ blood where it can be detected by measuring its components. Early diagnosis of AMI and other myocardial injury associated diseases related to cardiac muscle injury are important for immediate evidence-based therapy. Cardiac troponins I and T (cTnI and cTnT) are currently widely used as a recommended marker of AMI, other myocardial injury associated with postoperative myocardium trauma and many other diseases related to cardiac muscle injury diagnostics. The cTnI has been a gold standard and diagnostic cornerstone in the clinical assessment of AMI as it offers accurate and rapid diagnostics rule out.

Read more
31 Jan, 2022
Happy Chinese New Year!

Happy Chinese New Year!

Read more
27 Jan, 2022
New Product: Recombinant Cardiac Troponin Binary Complex

HyTest offers a new recombinant cardiac troponin binary complex (rec. cTn IC complex, Cat.# 8ICR3). The new complex is constructed from recombinant cTnI, and TnC isoforms. Resulting complex separated from free recombinant cTnI and TnC isoforms.

Read more
20 Dec, 2021
Season's Greetings 2021

We wish you a wonderful holiday season and a happy new year 2022!

This year, we decided to donate our Christmas present funds to lonely elderly and gave a gift of companionship:

Read more
30 Nov, 2021
New D-dimer Pair Recommendations

Our scientist has discovered new pairs for D-dimer immunoassay development for both chemiluminescence and lateral flow platforms.

Read more
30 Nov, 2021
Meet our Team at Medlab Middle East 2022

We will be attending Medlab Middle East 2022 in the end of January.

Read more
01 Nov, 2021
New Recombinant Troponin ITC Complex Available

Acute myocardial infarction (AMI) causes heart muscle damage and the release of troponin complex that can be detected in patients' blood by the measurement of its components. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT).

Read more
29 Oct, 2021
New product launch: PCT and calcitonin clones

Procalcitonin (PCT) is the main marker of disorders that are accompanied by sepsis. The PCT levels in blood are elevated during the systemic inflammation. In addition, the concentration of PCT closely correlates with the severity of inflammation, which further supports the diagnostic value of the marker. While in normal conditions the amount of non-cleaved PCT in blood is low, it increases during systemic inflammation and sepsis.

Read more
05 Oct, 2021
Meet HyTest Team at MEDICA 2021

We will be attending Medica 2021 in November.

Read more
05 Oct, 2021
The Winner of the Third EFLM-HyTest Cardiac Marker Award

The winner of the third EFLM-HyTest Cardiac Marker award will be announced by the EFLM President during the Opening Ceremony of the 24rd IFCC-EFLM European Congress - EuroMedLab in Munich.

Read more
23 Sep, 2021
Mindray Completes Acquisition of HyTest

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ), a leading global provider of medical devices and solutions, has completed its previously announced acquisition of HyTest Invest Oy and its subsidiaries (“HyTest”), a global leading provider of antibodies and antigens.

Read more
30 Aug, 2021
HyTest is Donating Time and Joy to a Lonely Senior Citizen

The loneliness of elderly people is a problem in Finland, the homecountry of HyTest. We wanted to be a part of the solution. That is why HyTest is now collaborating with a Finnish company called Gubbe.

Read more
16 Aug, 2021
Meet HyTest Team at AACC 2021

We will be attending the 2021 AACC Annual Meeting & Clinical Lab Expo. The exhibition will be on August 26 - 30 in Atlanta.


Read more
07 Jul, 2021
New Feline SAA Antibodies

Serum amyloid A is the only major acute phase protein in cats. It can be used as a sensitive marker of inflammation.

Read more
17 May, 2021
HyTest to be Acquired by Mindray

HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years. In going forward, HyTest is committed to serving all of its customers and will continue to provide high-quality diagnostic raw materials as before.

Read more

Sign up to our newsletter

And be informed about new products and scientific findings

Thank you for your subscription!